Skip to content

US · OSUR · MEDICAL - INSTRUMENTS & SUPPLIES

OraSure Technologies, Inc. (OSUR) intrinsic value and stock valuation

$3.46as of 2026-11-21 · Mkt cap 278.84M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

OraSure Technologies, Inc. DCF and intrinsic value

InvestorsCraft values OSUR with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OSUR’s statements →

OraSure Technologies, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Bethlehem, PA 18015 orasure.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$115M-7.7% 5y CAGRd
20112025
Net income
-$-68.73M
20112025
Free cash flow
-$-50K
20112025
Total equity
$340.8M-3.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$115M$185.8M$405.5M$387.5M$233.7M
Operating income-$-68.12M-$-20.6M$54.1M-$-5.24M-$-11.65M
Net income-$-68.73M-$-19.5M$53.7M-$-17.13M-$-23M
EPSd-$-935.36K-$-261.99K$721.3K-$-236.28K-$-319.53K
Operating cash flow-$-50K$27.4M$141.6M-$-47.2M-$-35.38M
Capital expenditure-$0.00-$-3.8M-$-10.3M-$-63.91M-$-48.12M
Free cash flow-$-50K$23.6M$131.3M-$-111.11M-$-83.5M
Total assets$403.2M$479.7M$482.9M$444.2M$461M
Total debt$13.2M$14.6M$13.5M$12.6M$12.3M
Net debt-$-186.08M-$-253.16M-$-276.9M-$-71.43M-$-104.49M
Total equity$340.8M$410.3M$430.7M$364.4M$380.5M
Cash and short-term investments$199.3M$267.8M$290.4M$110.9M$153M
Income statement
20252024202320222021
Revenue$115M$185.8M$405.5M$387.5M$233.7M
Cost of revenue$66.8M$109.6M$226.1M$239M$116.1M
Gross profit$48.2M$76.2M$179.4M$148.4M$117.6M
Research and development expenses$42.5M$24.4M$33.2M$36.2M$34.2M
Selling, general and administrative expenses$73.8M$72.4M$92.2M$117.4M$95.1M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$116.3M$96.8M$125.3M$153.7M$129.3M
Cost and expenses$183.2M$206.4M$351.4M$392.7M$245.3M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$9.97M$10.9M$19.9M$14M$11.7M
Ebitda-$-56.96M-$-6.83M$76.2M-$-1.68M$2.37M
Operating income-$-68.12M-$-20.6M$54.1M-$-5.24M-$-11.65M
Total other income/expenses, net$1.19M$2.9M$2.18M-$-10.43M$2.36M
Income before tax-$-66.93M-$-17.7M$56.3M-$-15.68M-$-9.29M
Income tax expense$1.8M$1.8M$2.6M$1.46M$13.7M
Net income-$-68.73M-$-19.5M$53.7M-$-17.13M-$-23M
Weighted average shares outstanding$73.5M$74.4M$73.4M$72.5M$72M
Weighted average diluted shares outstanding$73.5M$74.4M$74.4M$72.5M$72M
Balance sheet
20252024202320222021
Cash and short-term investments$199.3M$267.8M$290.4M$110.9M$153M
Net receivables$22.2M$23.8M$40.2M$70.8M$45.3M
Inventory$31.1M$34.2M$47.6M$95.7M$53.1M
Total current assets$261.9M$333.2M$386.5M$325.2M$299.3M
Property, plant and equipment, net$51.3M$58.7M$58.3M$71.1M$85M
Goodwill and intangible assets$62.4M$57.8M$36.9M$46.8M$54.6M
Long-term investments$26M$28.3M$0.00$0.00$17M
Total non-current assets$141.3M$146.4M$96.4M$119M$161.7M
Total assets$403.2M$479.7M$482.9M$444.2M$461M
Accounts payable$6.52M$8.17M$13.2M$38M$28M
Short-term debt$2.23M$2.17M$2.12M$2.94M$3.12M
Deferred revenue$1.52M$2.96M$1.56M$2.27M$2.94M
Total current liabilities$39.8M$33.5M$39.5M$69.1M$68.1M
Long-term debt$11M$12.4M$11.4M$9.6M$9.15M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$22.6M$35.8M$12.6M$10.7M$12.4M
Capital lease obligations$13.2M$14.6M$13.5M$12.6M$12.3M
Total liabilities$62.3M$69.3M$52.2M$79.8M$80.5M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-172.16M-$-103.43M-$-83.93M-$-137.59M-$-120.45M
Accumulated other comprehensive income (loss)-$-18.4M-$-24.36M-$-14.94M-$-18.43M-$-10.08M
Total equity$340.8M$410.3M$430.7M$364.4M$380.5M
Total investments$26M$28.3M$0.00$26.9M$53.3M
Total debt$13.2M$14.6M$13.5M$12.6M$12.3M
Net debt-$-186.08M-$-253.16M-$-276.9M-$-71.43M-$-104.49M
Cash flow statement
20252024202320222021
Net income-$-70K-$-19.5M$53.7M-$-17.93M-$-23M
Depreciation and amortization$10K$10.9M$20.9M$15.5M$12.5M
Stock-based compensation$10K$11.9M$10.7M$11.6M$7.81M
Change in working capital-$-6.8M$18.8M$45.8M-$-70.56M-$-38.44M
Accounts receivable$1.95M$15.9M$31.1M-$-25.16M-$-6.45M
Inventory$3.56M$13.1M$48.2M-$-43.05M-$-27.94M
Accounts payable-$-1.72M-$-7.58M-$-26.98M$3.96M$3.23M
Net cash provided by operating activities-$-50K$27.4M$141.6M-$-47.2M-$-35.38M
Investments in property, plant and equipment-$0.00-$-3.8M-$-10.3M-$-63.91M-$-48.12M
Acquisitions, net-$0.00-$-5.04M$0.00$120K$0.00
Net cash used for investing activities-$-10K-$-39.03M$66.2M$21.1M-$-5.5M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-15.04M-$-3.55M-$-1.9M-$-2.25M-$-2.11M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-20K-$-4.18M-$-3.02M-$-3.83M-$-2.82M
Net change in cash-$-70K-$-22.64M$206.4M-$-32.78M-$-44.04M
Cash at end of period$200K$267.8M$290.4M$84M$116.8M
Operating cash flow-$-50K$27.4M$141.6M-$-47.2M-$-35.38M
Capital expenditure-$0.00-$-3.8M-$-10.3M-$-63.91M-$-48.12M
Free cash flow-$-50K$23.6M$131.3M-$-111.11M-$-83.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About OraSure Technologies, Inc.

        OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

        CEO
        Carrie Eglinton Manner
        Employees
        501
        Beta
        1.00

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of OraSure Technologies, Inc. (OSUR)?

        OraSure Technologies, Inc. (OSUR) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is OSUR undervalued?

        OSUR trades at a price of $3.46 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.